The endocannabinoid system as a target for therapeutic drugs

被引:337
作者
Piomelli, D [1 ]
Giuffrida, A
Calignano, A
de Fonseca, FR
机构
[1] Univ Calif Irvine, Irvine, CA 92697 USA
[2] Univ Naples Federico II, Dept Pharmacol, I-80131 Naples, Italy
[3] Univ Naples Federico II, Dept Expt Pharmacol, I-80131 Naples, Italy
[4] Univ Complutense, Dept Psychobiol, Madrid 28233, Spain
关键词
D O I
10.1016/S0165-6147(00)01482-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cannabinoid receptors, the molecular targets of the cannabis constituent Delta(9)-tetrahydrocannabinol, are present throughout the body and are normally bound by a family of endogenous lipids - the endocannabinoids, Release of endocannabinoids is stimulated in a receptor-dependent manner by neurotransmitters and requires the enzymatic cleavage of phospholipid precursors present in the membranes of neurons and other cells. Once released, the endocannabinoids activate cannabinoid receptors on nearby cells and are rapidly inactivated by transport and subsequent enzymatic hydrolysis. These compounds might act near their site of synthesis to serve a variety of regulatory functions, some of which are now beginning to be understood. Recent advances in the biochemistry and pharmacology of the endocannabinoid system in relation to the opportunities that this system offers for the development of novel therapeutic agents will be discussed.
引用
收藏
页码:218 / 224
页数:7
相关论文
共 66 条
[1]   (R)-METHANANDAMIDE - A CHIRAL NOVEL ANANDAMIDE POSSESSING HIGHER POTENCY AND METABOLIC STABILITY [J].
ABADJI, V ;
LIN, SY ;
TAHA, G ;
GRIFFIN, G ;
STEVENSON, LA ;
PERTWEE, RG ;
MAKRIYANNIS, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (12) :1889-1893
[2]   CANNABIS AND SCHIZOPHRENIA - A LONGITUDINAL-STUDY OF SWEDISH CONSCRIPTS [J].
ANDREASSON, S ;
ENGSTROM, A ;
ALLEBECK, P ;
RYDBERG, U .
LANCET, 1987, 2 (8574) :1483-1486
[3]   Functional role of high-affinity anandamide transport, as revealed by selective inhibition [J].
Beltramo, M ;
Stella, N ;
Calignano, A ;
Lin, SY ;
Makriyannis, A ;
Piomelli, D .
SCIENCE, 1997, 277 (5329) :1094-1097
[4]   Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor [J].
Beltramo, M ;
de Fonseca, FR ;
Navarro, M ;
Calignano, A ;
Gorriti, MA ;
Grammatikopoulos, G ;
Sadile, AG ;
Giuffrida, A ;
Piomelli, D .
JOURNAL OF NEUROSCIENCE, 2000, 20 (09) :3401-3407
[5]   Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528 -: Implications for receptor biological responses [J].
Bouaboula, M ;
Dussossoy, D ;
Casellas, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (29) :20397-20405
[6]   Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease [J].
Brotchie, JM .
MOVEMENT DISORDERS, 1998, 13 (06) :871-876
[7]   Potentiation of anandamide hypotension by the transport inhibitor, AM404 [J].
Calignano, A ;
LaRana, G ;
Beltramo, M ;
Makriyannis, A ;
Piomelli, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 337 (01) :R1-R2
[8]   Control of pain initiation by endogenous cannabinoids [J].
Calignano, A ;
La Rana, G ;
Giuffrida, A ;
Piomelli, D .
NATURE, 1998, 394 (6690) :277-281
[9]   THE ACTION OF SYNTHETIC CANNABINOIDS ON THE INDUCTION OF LONG-TERM POTENTIATION IN THE RAT HIPPOCAMPAL SLICE [J].
COLLINS, DR ;
PERTWEE, RG ;
DAVIES, SN .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 259 (03) :R7-R8
[10]   Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides [J].
Cravatt, BF ;
Giang, DK ;
Mayfield, SP ;
Boger, DL ;
Lerner, RA ;
Gilula, NB .
NATURE, 1996, 384 (6604) :83-87